South Rampart Pharma Information

South Rampart Pharma, Inc. is a clinical-stage biotech company focused on addressing the critical need for a safe and effective approach to relieving pain. Its lead clinical candidate, SRP-001, is a novel, first-in-class analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region. SRP-001 influences pain-related genes through endocannabinoid, mechanical nociception, and fatty acid amide hydrolase pathways in the PAG region. Unlike opioids, SRP-001 doesn't carry a risk of abuse and addiction. Moreover, it lacks the hepatotoxicity associated with acetaminophen as it does not produce the harmful metabolite NAPQI nor disrupt liver cell tight junctions. Compared with acetaminophen, SRP-001 exhibits similar analgesic properties without the risk of liver damage, and it lacks NSAIDs’ kidney toxicity risk. SRP-001 is effective in different pain models, including the inflammatory von Frey, visceral, and somatic pain models. Interim results from the ongoing Phase 1 trials (NCT05484414) demonstrate SRP-001's safety, tolerability, and favorable pharmacokinetics. SRP-001 represents a promising alternative to existing pain medicines like acetaminophen, NSAIDs, and opioids, potentially providing a safer, more effective pain treatment option.